{
    "clinical_study": {
        "@rank": "20140", 
        "arm_group": [
            {
                "arm_group_label": "X0002", 
                "arm_group_type": "Experimental", 
                "description": "8.75 mg X0002/knee (2 sprays/knee, one spray to the medial surface and one spray to the lateral surface of the knee), BID, 17.5 mg X0002/knee (4 sprays/knee, one spray to the medial surface and one spray to the lateral surface of the knee, and one spray to front of the knee and one spray to the back of the knee), BID, or 35 mg X0002/knee (8 sprays/knee, each spray is to be applied to a different non-overlapping area around the knee, and the areas are to be uniformly distributed around the knee), BID will be applied to the knee transdermally"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "8.75 mg placebo powder/knee (2 sprays/knee, one spray to the medial surface and one spray to the lateral surface of the knee), BID, 17.5 mg placebo powder/knee (4 sprays/knee, one spray to the medial surface and one spray to the lateral surface of the knee, and one spray to front of the knee and one spray to the back of the knee), BID, or 35 mg placebo powder/knee (8 sprays/knee, each spray is to be applied to a different non-overlapping area around the knee, and the areas are to be uniformly distributed around the knee), BID will be applied to the knee transdermally"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a phase 2, multicenter, randomized, double blind (with dose), placebo controlled,\n      parallel group, proof of concept, and dose range finding study to evaluate the efficacy,\n      safety, and PK of X0002 spray in adult subjects with clinically symptomatic mild to moderate\n      OA of the knee.\n\n      Objectives of the study:\n\n        1. To evaluate the efficacy of X0002 spray compared to placebo for relief of knee pain in\n           subjects with osteoarthritis (OA) of the knee;\n\n        2. To assess the safety and tolerability of multiple doses of X0002 when administered as a\n           topical spray."
        }, 
        "brief_title": "A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteoarthritis of the Knee", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a phase 2, multicenter, randomized, double blind (with dose), placebo controlled,\n      parallel group, proof of concept, and dose range finding study to evaluate the efficacy,\n      safety, and PK of X0002 spray in adult subjects with clinically symptomatic mild to moderate\n      OA of the knee.\n\n      After a screening period of up to 3 weeks and radiographic evaluation of the target knee\n      joint space, 225 subjects will be randomly assigned to 1 of 3 treatment groups in a 1:1:1\n      ratio with a 2:1 ratio of active:placebo within each treatment group in a 1:1:1 ratio with a\n      2:1 ratio of active:placebo within each treatment group (i.e., 2 subjects to active\n      treatment and 1 subject to placebo):\n\n      Group A: 8.75 mg X0002/knee (2 sprays/knee, one spray to the medial surface and one spray to\n      the lateral surface of the knee), twice daily (BID, approximately every 12 hours; n=50) or\n      placebo (2 sprays/knee), BID (approximately every 12 hours; n=25) for a total of 4 sprays\n      per knee per day; Group B: 17.5 mg X0002/knee (4 sprays/knee, one spray to the medial\n      surface and one spray to the lateral surface of the knee, and one spray to front and one\n      spray to the back of the knee), BID (approximately every 12 hours; n=50) or placebo (4\n      sprays/knee), BID (approximately every 12 hours; n=25) for a total of 8 sprays per knee per\n      day; Group C: 35 mg X0002/knee (8 sprays/knee, each spray is to be applied to a different\n      non-overlapping area around the knee, and the areas are to be uniformly distributed around\n      the knee), BID (approximately every 12 hours; n=50) or placebo (8 sprays/knee), BID\n      (approximately every 12 hours; n=25) for a total of 16 sprays per knee per day.\n\n      Safety and efficacy assessments will be performed at at 2, 4, 8, and 12 weeks of treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A subject must be a male or female between 35 and 85 years of age, inclusive.\n\n          -  A subject must have a body mass index (BMI) between 18.5 and 39.9 kg/m2, inclusive.\n\n          -  A subject must have a diagnosis of idiopathic OA according to the American College of\n             Rheumatology (ACR) clinical and radiographic criteria (knee pain, osteophytes, and at\n             least one of the following: >50 years of age, morning stiffness lasting <30 minutes\n             after getting up in the morning, or crepitus).\n\n          -  A subject must have a Kellgren Lawrence Grade of 1 or 2 as determined by the\n             Investigator or a local radiologist at Screening.\n\n          -  A subject must have a history of clinically symptomatic mild to moderate OA of the\n             knee for \u22656 months.\n\n          -  A subject must have had knee pain while standing, walking, and/or on motion for at\n             least 14 days during the month prior to Screening.\n\n          -  A subject must have a knee pain score \u226540 mm and <90 mm on a 100 mm VAS (with or\n             without analgesic medication) on at least 10 of the 14 days  prior to randomization.\n\n          -  A subject must be willing to discontinue any NSAIDs or other analgesic (eg, aspirin,\n             acetaminophen) or potentially confounding concomitant treatments (eg, physiotherapy,\n             acupuncture) starting 4 days before the administration of the first dose of study\n             medication until completing participation in the study. (The use of \u2264325 mg\n             acetylsalicylic acid per day as cardiac prophylaxis is permitted.) The subject will\n             be allowed to take rescue medication (acetaminophen) for pain during the study except\n             during the 24 hours prior to Baseline (Day1), Week 2, Week 4, Week 8, Week 12/EOS,\n             and Follow-up assessments.\n\n          -  A subject must be willing to avoid unaccustomed physical activity (eg, starting a new\n             weight lifting routine) for the duration of the study.\n\n        Exclusion Criteria:\n\n          -  A subject who has secondary OA of the knee or OA of lower limb joints other than the\n             knee that, in the opinion of the Investigator, could interfere with pain and\n             functional assessments related to the knee\n\n          -  A subject who has OA of the knee with a Kellgren Lawrence Grade \u22653 as determined by\n             the Investigator or a local radiologist at Screening\n\n          -  A subject who has a history of total or partial knee replacement, arthroplasty, or\n             other knee surgery on either knee\n\n          -  A subject who has had significant injury, as judged by the Investigator, involving\n             the target knee within the 6 months before Screening.\n\n          -  A subject who has skin lesions or wounds on or near the knees to be treated at\n             Screening or on Day 1 prior to the first administration of study medication\n\n          -  A subject who has used opiates or corticosteroids within 30 days before Screening or\n             who requires treatment with chronic opiates or corticosteroids\n\n          -  A subject who has had intra articular injections of corticosteroids, hyaluronic acid,\n             or viscosupplements (eg, Synvisc\u00ae) to a knee to be treated within the 3 months before\n             Screening.\n\n          -  A subject who has a history of significant hypersensitivity, intolerance, or allergy\n             to ibuprofen, any NSAIDs, aspirin, or acetaminophen\n\n          -  A subject who has had an active peptic ulceration in the 12 months prior to Screening\n             or a history of gastrointestinal (GI) bleeding within 5 years of Screening\n\n          -  A subject who has used an anticoagulant (except aspirin up to 325 mg/day for cardiac\n             prophylaxis) in the month prior to Screening\n\n          -  A subject who has positive results on fecal occult blood testing at Screening or on\n             Day 1 prior to the first administration of study medication\n\n          -  A subject who has a history of chronic inflammatory disease (such as rheumatoid\n             arthritis, psoriatic arthritis, gouty arthritis), fibromyalgia, conditions that may\n             affect the target joint (eg, osteonecrosis, chondrocalcinosis), or asthma."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "225", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02067611", 
            "org_study_id": "TF-X0002-21"
        }, 
        "intervention": [
            {
                "arm_group_label": "X0002", 
                "description": "Parallel Assignment", 
                "intervention_name": "X0002", 
                "intervention_type": "Drug", 
                "other_name": "Ibuprofenamine"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Parallel Assignment", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo powder"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Phase 2, Efficacy, Safety, Osteoarthritis", 
        "lastchanged_date": "February 19, 2014", 
        "location": [
            {
                "contact": {
                    "email": "nicoleditulliomerrill@crastudies.com", 
                    "last_name": "Nicole DiTullio-Merrill", 
                    "phone": "480-831-6328"
                }, 
                "contact_backup": {
                    "email": "tfiel@crastudies.com", 
                    "last_name": "Thomas Fiel, MD", 
                    "phone": "4808316328"
                }, 
                "facility": {
                    "address": {
                        "city": "Tempe", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85283-1528"
                    }, 
                    "name": "Fiel Family & Sports Medicine/Clinical Research Advantage Inc"
                }, 
                "investigator": {
                    "last_name": "Thomas Fiel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lesliemellor@me.com", 
                    "last_name": "Leslie Mellor", 
                    "phone": "916-966-7452"
                }, 
                "contact_backup": {
                    "email": "drchamp@gxsolutions.com", 
                    "last_name": "John Champlin, MD", 
                    "phone": "9169667452"
                }, 
                "facility": {
                    "address": {
                        "city": "Carmichael", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95608"
                    }, 
                    "name": "Med Center"
                }, 
                "investigator": {
                    "last_name": "John Champlin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "twhited@ecrstudies.com", 
                    "last_name": "Teri Whited", 
                    "phone": "619-660-9068"
                }, 
                "contact_backup": {
                    "email": "rlipetz@ecrstudies.com", 
                    "last_name": "Robert Lipetz, MD", 
                    "phone": "6196609068"
                }, 
                "facility": {
                    "address": {
                        "city": "Spring Valley", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91978"
                    }, 
                    "name": "Encompass Clinical Research"
                }, 
                "investigator": {
                    "last_name": "Robert Lipetz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cmorimoto@diabloclinical.com", 
                    "last_name": "Catherine Morimoto", 
                    "phone": "925-930-7267"
                }, 
                "contact_backup": {
                    "email": "rweinstein@diabloclinical.com", 
                    "last_name": "Richard Weinstein, MD", 
                    "phone": "9259307267"
                }, 
                "facility": {
                    "address": {
                        "city": "Walnut Creek", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94598"
                    }, 
                    "name": "Diablo Clinical Research, Inc."
                }, 
                "investigator": {
                    "last_name": "Richard Weinstein, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "j.charles@neresearch.org", 
                    "last_name": "Janette Charles", 
                    "phone": "203-374-9816"
                }, 
                "contact_backup": {
                    "email": "geoffgla1@gmail.com", 
                    "last_name": "Geoffrey Gladstein, MD", 
                    "phone": "2033749816"
                }, 
                "facility": {
                    "address": {
                        "city": "Trumbull", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06611"
                    }, 
                    "name": "New England Research Assoc."
                }, 
                "investigator": {
                    "last_name": "Geoffrey Gladstein, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "teresa@CRSouthFlorida.com", 
                    "last_name": "Maria Teresa Valencia", 
                    "phone": "305-445-5637", 
                    "phone_ext": "240"
                }, 
                "contact_backup": {
                    "email": "mariarodriguez@CRSouthFlorida.com", 
                    "last_name": "Jeffrey Rosen", 
                    "phone": "3054455637"
                }, 
                "facility": {
                    "address": {
                        "city": "Coral Gables", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32720"
                    }, 
                    "name": "Clinical Research of South Florida"
                }, 
                "investigator": {
                    "last_name": "Jeffrey Rosen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "acevera@availclinical.com", 
                    "last_name": "Alicia Cevera", 
                    "phone": "386-740-0770", 
                    "phone_ext": "310"
                }, 
                "contact_backup": {
                    "email": "brankin@availclinical.com", 
                    "last_name": "Bruce Rankin, MD", 
                    "phone": "3867852381"
                }, 
                "facility": {
                    "address": {
                        "city": "Deland", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32720"
                    }, 
                    "name": "Avail Clinical Research, LLC"
                }, 
                "investigator": {
                    "last_name": "Bruce Rankin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kim@healthawarenessinc.com", 
                    "last_name": "Kim Smith", 
                    "phone": "561-741-2033"
                }, 
                "contact_backup": {
                    "email": "gcpinvestigator@gmail.com", 
                    "last_name": "Ronald Surowitz, MD", 
                    "phone": "5617412033"
                }, 
                "facility": {
                    "address": {
                        "city": "Jupiter", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33458"
                    }, 
                    "name": "Health Awareness Inc."
                }, 
                "investigator": {
                    "last_name": "Ronald Surowitz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rburfeind@suncoastclinicalresearch.com", 
                    "last_name": "Robert Burfeind", 
                    "phone": "727-849-4134"
                }, 
                "contact_backup": {
                    "email": "lcohen@suncoastclinicalresearch.com", 
                    "last_name": "Lisa Cohen", 
                    "phone": "7278440577"
                }, 
                "facility": {
                    "address": {
                        "city": "New Port Richey", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34652"
                    }, 
                    "name": "Suncoast Clinical Research, Inc"
                }, 
                "investigator": {
                    "last_name": "Lisa Cohen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "aclary@serrg.com", 
                    "last_name": "Amanda Clary", 
                    "phone": "706-596-4894"
                }, 
                "contact_backup": {
                    "email": "columbus@serrg.com", 
                    "last_name": "David Subich, MD", 
                    "phone": "7065964894"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "31904"
                    }, 
                    "name": "Columbus Regional Research Institute"
                }, 
                "investigator": {
                    "last_name": "David Subich, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mthomas@cttresearch.com", 
                    "last_name": "Kim Smith", 
                    "phone": "561-741-2033"
                }, 
                "contact_backup": {
                    "email": "mthomas@cttresearch.com", 
                    "last_name": "Haydn Mike Thomas, MD", 
                    "phone": "9133817180"
                }, 
                "facility": {
                    "address": {
                        "city": "Prairie Village", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66206-1362"
                    }, 
                    "name": "Clinical Trials Technology(CTT) Consultants, Inc."
                }, 
                "investigator": {
                    "last_name": "Mike Thomas, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bspringer@healthcareresearchnetwork.com", 
                    "last_name": "Brian Springer", 
                    "phone": "314-972-9600"
                }, 
                "contact_backup": {
                    "email": "larryreed@aol.com", 
                    "last_name": "Larry Reed, MD", 
                    "phone": "3149729600"
                }, 
                "facility": {
                    "address": {
                        "city": "Hazelwood", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63042-1755"
                    }, 
                    "name": "Healthcare Research Network"
                }, 
                "investigator": {
                    "last_name": "Larry Reed, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cshultz@sundanceclinicalresearch.com", 
                    "last_name": "Christy Schultz", 
                    "phone": "314-567-3377"
                }, 
                "contact_backup": {
                    "email": "ty.wadsworth@sbcglobal.net", 
                    "last_name": "Larkin Wadsworth, MD", 
                    "phone": "3145673377"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63141-7068"
                    }, 
                    "name": "Sundance Clinical Research, LLC"
                }, 
                "investigator": {
                    "last_name": "Larkin Wadsworth, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "researchrudolph@nmbonecare.com", 
                    "last_name": "Lance Rudolph, MD", 
                    "phone": "505-855-5505"
                }, 
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico", 
                        "zip": "87106"
                    }, 
                    "name": "New Mexico Clinical Research & Osteoporosis Center, Inc."
                }, 
                "investigator": {
                    "last_name": "Lance Rudolph, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tstalls.hightop@gmail.com", 
                    "last_name": "Tara Stallmeyer", 
                    "phone": "513-681-0606"
                }, 
                "contact_backup": {
                    "email": "jamesfidelholtz@gmail.com", 
                    "last_name": "James Fidelholtz, MD", 
                    "phone": "5136810606"
                }, 
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45224"
                    }, 
                    "name": "Hightop Medical Research"
                }, 
                "investigator": {
                    "last_name": "James Fidelholtz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "melissa_twine@yahoo.com", 
                    "last_name": "Melissa Twine", 
                    "phone": "937-746-4505"
                }, 
                "contact_backup": {
                    "email": "gary_bedel@yahoo.com", 
                    "last_name": "Gary Bedel, MD", 
                    "phone": "9377464505"
                }, 
                "facility": {
                    "address": {
                        "city": "Franklin", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45005"
                    }, 
                    "name": "Prestige Clinical Research, LLC"
                }, 
                "investigator": {
                    "last_name": "Gary Bedel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ddesalle@hvhs.org", 
                    "last_name": "Dina DeSalle", 
                    "phone": "724-774-7743"
                }, 
                "contact_backup": {
                    "email": "dmichael@hvhs.org", 
                    "last_name": "Timothy Jackson, MD", 
                    "phone": "7247747743"
                }, 
                "facility": {
                    "address": {
                        "city": "Beaver", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15009"
                    }, 
                    "name": "Heritage Valley Medical Group"
                }, 
                "investigator": {
                    "last_name": "Timothy Jackson, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ajkivitz@yahoo.com", 
                    "last_name": "Alan Kivitz, MD", 
                    "phone": "814-693-0300"
                }, 
                "contact_backup": {
                    "email": "altoonaresearch@gmail.com", 
                    "last_name": "Lisa Claycomb", 
                    "phone": "8142966101"
                }, 
                "facility": {
                    "address": {
                        "city": "Duncansville", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "16635"
                    }, 
                    "name": "Altoona Center for Clinical Research"
                }, 
                "investigator": {
                    "last_name": "Alan Kivitz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "leishalaroux@qualityresearchinc.com", 
                    "last_name": "Leisha Laroux", 
                    "phone": "210-824-5678"
                }, 
                "contact_backup": {
                    "email": "scotthorn@qualityresearchinc.com", 
                    "last_name": "Scott Curtis Horn", 
                    "phone": "2108245678"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78209"
                    }, 
                    "name": "Quality Research Inc"
                }, 
                "investigator": {
                    "last_name": "Scott Curtis Horn, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lporter@hrhr-inc.com", 
                    "last_name": "Leslie Porter", 
                    "phone": "757-591-8100"
                }, 
                "contact_backup": {
                    "email": "clfisher@hrhr-inc.com", 
                    "last_name": "Chester Fisher, MD", 
                    "phone": "7575918100"
                }, 
                "facility": {
                    "address": {
                        "city": "Newport News", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23606"
                    }, 
                    "name": "Health Research of Hampton Roads, Inc"
                }, 
                "investigator": {
                    "last_name": "Chester Fisher, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Range Finding Study to Evaluate the Efficacy and Safety of X0002 Spray Versus Placebo in Subjects With Osteoarthritis", 
        "other_outcome": [
            {
                "description": "Data for the exploratory efficacy endpoints will be summarized using descriptive statistics.\nSafety analyses will be conducted on the SAS. Safety parameters will be listed and summarized using standard descriptive statistics, as appropriate. No formal statistical analyses are planned.", 
                "measure": "Subject's global assessment of disease status of the target knee at 2, 4, 8 and 12 weeks of treatment", 
                "safety_issue": "Yes", 
                "time_frame": "at 2, 4, 8, and 12 weeks of treatment"
            }, 
            {
                "description": "Data for the exploratory efficacy endpoints will be summarized using descriptive statistics.\nSafety analyses will be conducted on the SAS. Safety parameters will be listed and summarized using standard descriptive statistics, as appropriate. No formal statistical analyses are planned.", 
                "measure": "Investigator's global assessment of disease status of the target knee at 2, 4, 8 and 12 weeks of treatment", 
                "safety_issue": "Yes", 
                "time_frame": "at 2, 4, 8, and 12 weeks of treatment"
            }, 
            {
                "description": "Data for the exploratory efficacy endpoints will be summarized using descriptive statistics.\nSafety analyses will be conducted on the SAS. Safety parameters will be listed and summarized using standard descriptive statistics, as appropriate. No formal statistical analyses are planned.", 
                "measure": "Subject's global assessment of response to therapy of the target knee at 2, 4, 8 and 12 weeks of treatment", 
                "safety_issue": "Yes", 
                "time_frame": "at 2, 4, 8, and 12 weeks of treatment"
            }, 
            {
                "description": "Data for the exploratory efficacy endpoints will be summarized using descriptive statistics.\nSafety analyses will be conducted on the SAS. Safety parameters will be listed and summarized using standard descriptive statistics, as appropriate. No formal statistical analyses are planned.", 
                "measure": "Investigator's global assessment of response to therapy of the target knee at 2, 4, 8 and 12 weeks of treatment", 
                "safety_issue": "Yes", 
                "time_frame": "at 2, 4, 8, and 12 weeks of treatment"
            }, 
            {
                "description": "Data for the exploratory efficacy endpoints will be summarized using descriptive statistics.\nSafety analyses will be conducted on the SAS. Safety parameters will be listed and summarized using standard descriptive statistics, as appropriate. No formal statistical analyses are planned.", 
                "measure": "Change from Baseline over time in VAS pain scores for the target knee from Daily Diary data.", 
                "safety_issue": "Yes", 
                "time_frame": "at 2, 4, 8, and 12 weeks of treatment"
            }, 
            {
                "description": "Data for the exploratory efficacy endpoints will be summarized using descriptive statistics.\nSafety analyses will be conducted on the SAS. Safety parameters will be listed and summarized using standard descriptive statistics, as appropriate. No formal statistical analyses are planned.", 
                "measure": "Amount of rescue medication (acetaminophen) consumed per day for target knee pain.", 
                "safety_issue": "Yes", 
                "time_frame": "at 2, 4, 8, and 12 weeks of treatment"
            }, 
            {
                "description": "Data for the exploratory efficacy endpoints will be summarized using descriptive statistics.\nSafety analyses will be conducted on the SAS. Safety parameters will be listed and summarized using standard descriptive statistics, as appropriate. No formal statistical analyses are planned.", 
                "measure": "Change from Baseline at 12 weeks of treatment in radiographic joint space of the target knee", 
                "safety_issue": "Yes", 
                "time_frame": "at 0 and 12 weeks of treatment"
            }
        ], 
        "overall_contact": {
            "email": "valerie.brooks@covance.com", 
            "last_name": "Valerie Brooks, CCRA, PMP", 
            "phone": "608-282-5501"
        }, 
        "overall_official": {
            "affiliation": "Techfields Inc", 
            "last_name": "Chongxi Yu, Ph.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The Primary Efficacy Endpoint is change from Baseline in the WOMAC (VAS) pain subscale score for the target knee at 4 weeks of treatment, and will be analyzed using an analysis of covariance (ANCOVA). Treatment will be included as a fixed class effect and WOMAC Baseline pain subscale score as covariates. The primary comparisons of interest will be the difference between active Group A (8.75 mg X0002/knee) and combined placebo, active Group B (17.5 mg X0002/knee) and combined placebo, and active Group C (35 mg X0002/knee) and combined placebo.\nSafety analyses will be conducted on the SAS. Safety parameters will be listed and summarized using standard descriptive statistics, as appropriate. No formal statistical analyses are planned.", 
            "measure": "To evaluate the efficacy of X0002 spray compared to placebo for relief of knee pain in subjects with osteoarthritis (OA) of the knee", 
            "safety_issue": "Yes", 
            "time_frame": "4 weeks of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02067611"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Techfields Pharma Co. Ltd", 
            "investigator_full_name": "Lina Xu", 
            "investigator_title": "Vice president", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "A sensitivity analysis will also be conducted on the Primary Efficacy Endpoint using an ANCOVA with treatment as a fixed class effect and WOMAC baseline pain subscale score as covariates, but the comparisons of interest will be the difference between the active and placebo subjects within each treatment group.\nThe Secondary Efficacy Endpoints, change from Baseline in the WOMAC subscale scores for pain, stiffness, and functional ability, and overall WOMAC score at 2, 8, and 12 weeks of treatment, will be by analyzed using the same methods as the for the Primary Efficacy Endpoint.\nSafety analyses will be conducted on the SAS. Safety parameters will be listed and summarized using standard descriptive statistics, as appropriate. No formal statistical analyses are planned.", 
                "measure": "To assess the safety and tolerability of multiple doses of X0002 when administered as a topical spray", 
                "safety_issue": "Yes", 
                "time_frame": "2, 8, and 12 weeks of treatment"
            }, 
            {
                "description": "A sensitivity analysis will also be conducted on the Primary Efficacy Endpoint using an ANCOVA with treatment as a fixed class effect and WOMAC baseline pain subscale score as covariates, but the comparisons of interest will be the difference between the active and placebo subjects within each treatment group.\nThe Secondary Efficacy Endpoints, change from Baseline in the WOMAC subscale scores for pain, stiffness, and functional ability, and overall WOMAC score at 2, 4, 8, and 12 weeks of treatment, will be by analyzed using the same methods as the for the Primary Efficacy Endpoint.\nSafety analyses will be conducted on the SAS. Safety parameters will be listed and summarized using standard descriptive statistics, as appropriate. No formal statistical analyses are planned.", 
                "measure": "To evaluate the effect of X0002 spray compared to placebo for the relief of joint stiffness", 
                "safety_issue": "Yes", 
                "time_frame": "2, 4, 8, and 12 weeks of treatment"
            }, 
            {
                "description": "A sensitivity analysis will also be conducted on the Primary Efficacy Endpoint using an ANCOVA with treatment as a fixed class effect and WOMAC baseline pain subscale score as covariates, but the comparisons of interest will be the difference between the active and placebo subjects within each treatment group.\nThe Secondary Efficacy Endpoints, change from Baseline in the WOMAC subscale scores for pain, stiffness, and functional ability, and overall WOMAC score at 2, 8, and 12 weeks of treatment, will be by analyzed using the same methods as the for the Primary Efficacy Endpoint.\nSafety analyses will be conducted on the SAS. Safety parameters will be listed and summarized using standard descriptive statistics, as appropriate. No formal statistical analyses are planned.", 
                "measure": "To assess the effect of X0002 spray compared to placebo on difficulty performing daily activities", 
                "safety_issue": "Yes", 
                "time_frame": "at 2, 4, 8, and 12 weeks of treatment"
            }, 
            {
                "description": "A sensitivity analysis will also be conducted on the Primary Efficacy Endpoint using an ANCOVA with treatment as a fixed class effect and WOMAC baseline pain subscale score as covariates, but the comparisons of interest will be the difference between the active and placebo subjects within each treatment group.\nThe Secondary Efficacy Endpoints, change from Baseline in the WOMAC subscale scores for pain, stiffness, and functional ability, and overall WOMAC score at 2, 8, and 12 weeks of treatment, will be by analyzed using the same methods as the for the Primary Efficacy Endpoint.\nSafety analyses will be conducted on the SAS. Safety parameters will be listed and summarized using standard descriptive statistics, as appropriate. No formal statistical analyses are planned.", 
                "measure": "To assess the onset and durability of response to X0002 on pain, stiffness, and difficulty performing daily activities", 
                "safety_issue": "Yes", 
                "time_frame": "at 2, 4, 8, and 12 weeks of treatment"
            }, 
            {
                "description": "Cmax, Tmax,  AUCs, apparent terminal elimination rate constant, apparent terminal elimination half-life will be calculated.", 
                "measure": "Characterize the pharmacokinetics of X0002", 
                "safety_issue": "Yes", 
                "time_frame": "at  the Week 2, week 3, week 4 and Week 12"
            }
        ], 
        "source": "Techfields Pharma Co. Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lina Xu", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}